Log In
BCIQ
Print this Print this
 

AJG501

  Manage Alerts
Collapse Summary General Information
Company Dr. Falk Pharma GmbH
DescriptionOnce-daily oral mesalazine granules
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat ulcerative colitis (UC)
Regulatory Designation
PartnerAjinomoto Co. Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today